FOCL FocalTherics

NASDAQ
$4.34

FocalTherics (FOCL) is confirmed to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.18 per share.

FocalTherics Beat Consensus Estimates, Narrows Guidance
Thursday, November 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.18)
Rev est $10.95M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.31

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About FocalTherics

EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors.

Sector

Healthcare

Industry

Medical Instruments/Supply

Charts powered in part by Lightweight Charts™ by TradingView.